| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Hansson, Kristofer, et al.
(författare)
-
CIT-PART: Report Case Study Sweden
- 2011
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- In the early 1990s xenotransplantation (XTP) was a promising biotechnology, with many countries prepared to take this research to clinical trials. It was also a technology associated with so many problems and risks that the researchers sought financial support to continue their XTP research. This was, in many ways, an international concern, as the researchers tried to collaborate to overcome those problems and risks. But despite this international effort, the situation became a national policy process in many countries where researchers, politicians and stakeholders tried to find a solution and take the next step in XTP research. In this case study, we take a closer look at Sweden and how the national policy process took shape in the 1990s. As we will see in this case study, Swedish XTP researchers and politicians were involved in various international networks, but when it came to initiating a more formal policy process, the discussion became more or less national. Swedish law needed to change so that the country‘s XTP researchers could continue with their research and take it to clinical trials. The policy process was closely linked to the idea that Sweden as a nation could gain an advantage, both for the researchers and for the state. The new biotechnology could benefit the citizens and provide future funding for the welfare society. To achieve this, Swedish researchers needed to be the first to clinically introduce this technology. So this case study is about how a nation tries to gain advantages in an international research arena. It is also a case study of what role the citizens have in the policy process. Biotechnology that is problematic and risky, for various reasons, needs the approval of the general public, because they will be the end users. In this case study, we take a closer look at how researchers and politicians interacted with the citizens in the policy process.
|
|
| 5. |
- Hansson, Kristofer, et al.
(författare)
-
Nordic countries: Denmark, Norway and Sweden
- 2010
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- The aims of the workpackage: The objective of WP3 is to provide an overview of policy formation and deliberation across a number of regions and across a relatively broad timeframe (late 1980s to the present). As a mapping exercise it is intended to provide an initial comparative framework for further elaboration in more detailed country and regional case studies. WP3 offers a ‗helicopter view‘ of global xenotransplantation (XTP) regulation and landmark policy events. It provides a history of the development and timeline of policy-making combined with an initial scoping of the place and purpose of consultative and deliberative processes. In so doing, the WP provides a means of initial orientation for future comparative work and more in depth case studies. The WP is in no sense intended to be comprehensive but instead provides an initial means of developing a more focussed comparative method and body of questions to be taken up in the project‘s future workpackages.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
- Lundin, Susanne, et al.
(författare)
-
Where and how do you buy medicines? : Report
- 2016
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- In order to understand where and how the Swedish public access their medicines, especially prescribed medicines, an online survey was conducted as a pilot study during April and May 2016. Among a collection of 155 answers, the data shows that, although a majority of the respondents feel hesitated and negative towards shopping prescribed medicines online, a tendency is demonstrated that people would seek out medical assistance from other sources in foreign countries if their need could not be satisfied by the current national healthcare service. This might expose these vulnerable patients to the danger of falsified medicines. Our findings point out the need to map out medical consumers’ shopping patterns and call for more qualitative studies to understand this mechanism and to provide the public with necessary information regarding shopping medicines in a safe environment.
|
|
